Colorectal cancer (CRC) remains one of the primary causes of cancer-related deaths worldwide \[[@CR1]\]. Although surgery remains the best treatment choice, a significant majority of stage II and III CRC patients develop disease recurrence following a curative resection; highlighting the inadequacy of currently used TNM classification for patient prognostication. Due to the high recurrence rates, patients with stage III disease routinely receive adjuvant chemotherapy \[[@CR2]\]. Even though a clear benefit of adjuvant treatment in stage II CRC patients remains debatable, adjuvant chemotherapy is thought to be a reasonable treatment modality for the subgroup of high-risk stage II patients \[[@CR3]\]. Nonetheless, given the relatively poor therapeutic response and high cancer recurrence rates, the current histopathological risk-stratification criteria remain inadequate. To address this concern, researchers have attempted to develop various biomarkers for patient stratification \[[@CR4]\]; however, due a variety of biological and technical reasons, most of these biomarkers fail independent validations and are hence still not adopted in the clinical settings.

Epithelial-to-mesenchymal transition (EMT) is considered an essential regulatory process that mediates invasion and metastasis in cancer \[[@CR5]\]. Recently, four consensus molecular subtypes (CMS) were identified in CRC patients following a comprehensive gene expression profiling \[[@CR6]\]. Among these subgroups, the CMS4 subtype, characterized by the upregulation of EMT-associated genes, unequivocally emerged as a distinct subtype with worse overall survival (OS) and relapse-free survival (RFS). Although CMS classification holds promise in future, at this time, its clinical application for risk-stratification in CRC patients remains unclear. Nonetheless, given the strong association of CMS4 subgroups with an EMT phenotype, there is an emerging interest to develop EMT-associated biomarkers, which may serve as surrogates for the CMS4 subtype, and may allow more improved patient stratification.

Recently, our group has shown that biomarkers highly expressed in liver metastasis are involved in distant metastasis and the EMT process \[[@CR7], [@CR8]\]. In this study, using a genomewide transcriptomic profiling of matched primary CRC and corresponding liver metastasis tissues, followed by their comparison in patients with and without disease recurrence, we identified a novel, EMT-related biomarker that robustly stratified low and high-risk CRC patients. Gene Set Enrichment Analysis (GSEA) revealed that high expression of integrin subunit beta like 1 (ITGBL1) strongly correlated with an EMT-phenotype, and significantly discriminated CRC patients with the CMS4 vs. the others subtypes. Subsequent clinical validation efforts revealed that high expression of *ITGBL1* associated with poor OS and RFS in multiple, large, independent CRC patient cohorts, which allowed us to conclude that ITGBL1 is an attractive and promising prognostic biomarker in CRC.

Results and discussion {#Sec1}
======================

Overexpression of metastatic-recurrence-related genes in CRC {#Sec2}
------------------------------------------------------------

We first used a systematic biomarker discovery step to identify metastatic recurrence-specific genes for CRC from the publicly available GSE17538 and GSE41258 datasets. We identified two genes, ITGBL1 and SPP1 (osteopontin), which were differentially expressed between the primary CRC vs. metastatic tissues, recurrence vs. non-recurrence groups and normal vs. cancers (\> 2 fold change, and adjusted *P* \< 0.05; Fig. [1](#Fig1){ref-type="fig"}a-c). Since, SPP1 has been extensively studied in CRC \[[@CR9]\], while the clinical significance of ITGBL1 remains poorly but gaining a lot of attention in the field of cancer research \[[@CR10]\], we selected ITGBL1 for further evaluation. The detailed methods are provided in the Additional file [1](#MOESM1){ref-type="media"}. The flow chart for the study design is illustrated in Additional file [2](#MOESM2){ref-type="media"}.Fig. 1Biomarker discovery analysis in this study. *ITGBL1* expression was upregulated in various biomarker discovery analysis, **a**) Primary vs. metastasis tissues, **b**) patients with vs. without tumor recurrence, and **c**) normal vs. cancer tissues. **d** Enrichment plots of GSEA correlation analyses for *ITGBL1* with EMT-associated gene sets using the GSE39582 dataset (left). Heatmap for the correlation of *ITGBL1* and representative EMT-related genes by GENE-E software (right). *ITGBL1* expression is upregulated in the CMS4 subtype of CRCs in the two public datasets, **e**) GSE39582 dataset, and **f**) GSE33113 dataset. \*\*\**P* \< 0.001. Relationship between *ITGBL1* expression and RFS among patients **g**) in all stage II CRC patients with the GSE39582 cohort, **h**) in MSS stage II CRC patients within the GSE39582 cohort, and **i**) in all stage II CRCs in the GSE33113 cohort

*ITGBL1* expression strongly correlates with an epithelial mesenchymal transition in CRC {#Sec3}
----------------------------------------------------------------------------------------

To gain further insight into the molecular function of ITGBL1 in CRC, we performed GSEA using genes that had a positive correlation with *ITGBL1* expression. Based on the normalized enrichment score (NES), the EMT gene set emerged to be most strongly correlated with *ITGBL1* expression (NES 2.099, *P* \< 0.001, False discovery rate 0.016; Fig. [1](#Fig1){ref-type="fig"}d). Interestingly, several additional EMT-associated genes were also significantly correlated with the *ITGBL1* expression (Fig. [1](#Fig1){ref-type="fig"}d); suggesting that ITGBL1 expression may serve as an important indicator of an EMT phenotype in CRC. Recent evidence indicates that an EMT phenotype is associated with the dissociation of the primary tumor cells from the primary site, followed by intravasation into blood and/or lymphatic vessels, establishing metastasis \[[@CR5]\]. Through such an EMT process, CRCs with High *ITGBL1* expression may lead to advanced disease, and present a higher risk for metastasis, which becomes the basis for developing recurrence prediction biomarkers.

*ITGBL1* serves as a surrogate for predicting the CMS4 subtype in CRC {#Sec4}
---------------------------------------------------------------------

We next evaluated the expression of *ITGBL1* in the context of CMS status in two public datasets (GSE39582 and GSE33113). We found that *ITGBL1* expression was specifically higher in the CMS4 subtype vs. other subtypes in both patient cohorts. The AUROC for distinguishing CMS4 vs. CMS1--3 subtypes in CRC were 0.84 in GSE39582 and 0.91 in GSE33113 (Fig. [1](#Fig1){ref-type="fig"}e and f).

*ITGBL1* expression associates with poor RFS in CRC patients {#Sec5}
------------------------------------------------------------

Furthermore, to investigate the clinical significance of *ITGBL1* expression for risk-stratification of disease recurrence in stage II CRC patients, the group in which adjuvant chemotherapy decision-making is most desirable, we analyzed RFS in patients from the GSE39582 and GSE33113 datasets (Fig. [1](#Fig1){ref-type="fig"}g and i, respectively). In line with our earlier findings, we observed that high *ITGBL1* expression group consistently demonstrated shorter RFS in stage II patients; yet again confirming the prognostic potential of this EMT-associated gene. In particular, based upon MSI analysis, high *ITGBL1* expression allowed identification of high-risk patients more effectively in microsatellite stable (MSS) stage II CRC patients vs. all stage II patients in the GSE39582 cohort (Fig. [1](#Fig1){ref-type="fig"}h**)**.

The ITGBL1 protein expression is specifically higher in metastatic tissues from CRC patients {#Sec6}
--------------------------------------------------------------------------------------------

For a better understanding of the expression pattern of ITGBL1, we performed immunohistochemical (IHC) analysis. We found that ITGBL1 expression in normal colonic mucosa was quite weak (Additional file [3](#MOESM3){ref-type="media"}: Figure S2D). However, ITGBL1 expression gradually increased from the luminal region to the invasive front in primary CRC, indicating that elevation of ITGBL1 expression might facilitate higher metastatic potential at the invasive front in primary CRC (Additional file [3](#MOESM3){ref-type="media"}: Figure S2A, B, and C). Likewise, liver metastasis revealed extremely high expression of ITGBL1 compared to adjacent hepatocytes (Additional file [3](#MOESM3){ref-type="media"}: Figure S2E).

High *ITGBL1* expression correlated with advanced stage, and presence of lymphovascular and distant metastasis in CRC patients {#Sec7}
------------------------------------------------------------------------------------------------------------------------------

We next investigated the level of *ITGBL1* expression in relationship with various clinicopathological variables in two independent clinical testing and validation cohorts of 669 CRC patients (Additional file [4](#MOESM4){ref-type="media"}: Table S1). High *ITGBL1* expression significantly correlated with increased tumor size, higher T stage, lymphovascular invasion, and the presence of distant metastasis in both cohorts (Table [1](#Tab1){ref-type="table"}). Furthermore, when all CRC patients were segregated based upon the TNM stage, a gradual increase in *ITGBL1* expression levels was observed from the low to high stages in both cohorts (Fig. [2](#Fig2){ref-type="fig"}a and d).Table 1Association between *ITGBL1* expression and clinicopathological factorsVariablesTesting cohort N (%)Validation cohort N (%)*ITGBL1* level*ITGBL1* levelLowHigh*P* valueLowHigh*P* valueN=130N=71N=256N=212Gender Male61290.41162113**0.03** Female69429499Age \<6580450.88114810.19 ≥655026142131Location Colon65360.921601310.88 Rectum65359681Histology Differentiated119680.392391910.23 Undifferentiated1131721Tumor size (mm) ≤458129**\<0.01**15172**\<0.0001** \>45494291137Unavailable00143T stage T1,T2377**\<0.01**6824**\<0.0001** T3,T49364188188Lymphovascular invasion Absent5511**\<0.0001**4116**\<0.01** Present7560213196Unavailable0020Lymph node Metastasis Absent6921**0.001**1371130.96 Present615011999Distant metastasis Absent12057**0.02**224163**\<0.01** Present10143249Stage I, II6718**\<0.001**1321030.52 III, IV6353124109Preoperative CEA (ng/ml) \<588390.071561140.12 5≤423210098Fig. 2ITGBL1 expression in testing and validation clinical cohorts. Box plots representing *ITGBL1* levels in different Tumor Node Metastasis (TNM) stages (I, II, III, and IV) in CRC: **a**) The testing cohort (*N* = 201), and **d**) The validation cohort (*N* = 468). \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. The prognostic significance of *ITGBL1* expression was evaluated in CRC patients from two independent clinical cohorts: **b**, **c**) testing cohort, and **e**, **f**) validation cohort. Relapse-free survival in stage I-III patients (**b** and **e**) and overall survival in stage I-IV patients (**c** and **f**) were performed using the Kaplan--Meier test and the log-rank method. Forest plot of each clinicopathological factors, *ITGBL1* expression for predicting RFS in stage II CRC patients of validation cohort: **g**) Univariate analysis, and **h**) Multivariate analysis. Relationship between *ITGBL1* expression and RFS in stage II CRC patients of validation cohort: **i**) all stage II CRC patients, and **j**) MSS stage II CRC patients. **k**) Time-dependent ROC curves comparing and combining the predicting accuracy for recurrence at 5 years in stage II CRC patients

Overexpression of *ITGBL1* correlated with poor survival in CRC patients {#Sec8}
------------------------------------------------------------------------

Next, we examined *ITGBL1* expression with regard to its prognostic significance in the testing (*n* = 201), and validation cohorts (*n* = 468). In both cohorts, we noted that high *ITGBL1* expression level correlated with shorter RFS in stage I-III patients (Fig. [2](#Fig2){ref-type="fig"}b and e), as well as a shorter OS in stage I-IV patients (Fig. [2](#Fig2){ref-type="fig"}c and f).

Cox's univariate and multivariate analyses for RFS showed that high *ITGBL1* expression was an independent prognostic factor for RFS in stage II CRC patients in the validation cohort (Additional file [5](#MOESM5){ref-type="media"}; Fig. [2](#Fig2){ref-type="fig"}g and h); and was also found to be significant in predicting RFS with a HR of 2.58 (Fig. [2](#Fig2){ref-type="fig"}i). Specifically, as evidenced from the findings of the GSE39582 dataset, high *ITGBL1* expression could effectively identify high-risk patients in microsatellite stable (MSS) stage II CRC patients, whose risk stratification is very crucial for decision-making of the adjuvant therapy (HR 3.16; Fig. [2](#Fig2){ref-type="fig"}j). Taken together, these findings indicate that high *ITGBL1* expression has important clinical significance and could potentially serve as an important biomarker for predicting recurrence in CRC patients.

We finally constructed a RFS prediction model with various combinations of parameters including *ITGBL1* expression using the Cox's proportional hazard model in stage II CRC patients. AUROC at five years of this prediction model including Rectum, T4, MSS and *ITGBL1* expression further improved from 0.61 to 0.74 (Fig. [2](#Fig2){ref-type="fig"}k); highlighting the recurrence predictive potential of *ITGBL1* in CRC.

Conclusion {#Sec9}
==========

In conclusion, high *ITGBL1* expression in primary tumors was associated with recurrence in CRC patients following curative surgery. Our study identified ITGBL1 as a novel, promising EMT-associated gene that could help in risk stratification and recurrence prediction in CRC patients.
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